The FDA has approved anastrozole (Arimidex, AstraZeneca Pharmaceuticals LP, Wilmington, Del) for adjuvant treatment of postmenopausal women with hormone receptor–positive early breast cancer. The drug, a nonsteroidal aromatase inhibitor, had been approved for two indications in postmenopausal women, including first-line treatment of locally advanced or metastatic breast cancer and treatment of advanced breast cancer in women with disease progression following tamoxifen therapy.
McClellan MB. Adjuvant Breast Cancer Treatment. JAMA. 2002;288(17):2112. doi:10.1001/jama.288.17.2112-JFD20011-2-1